Eriika Savontaus profile picture
Associate Professor, Institute of Biomedicine


+358 29 450 4659
+358 50 401 2195
Kiinamyllynkatu 10

Areas of expertise

drug therapeutics
cardiovascular diseases, in vivo disease models


Eriika Savontaus received MD in 1995 and PhD in 1999 at University of Turku. She got her post-doctoral training at Columbia University, Division of Molecular Genetics, New York, NY, USA 2000-2002. She established her own laboratory in the Department of Pharmacology and Clinical Pharmacology in 2003. Savontaus received the title of docent in Pharmacology in 2008. She has served as Senior/Clinical Lecturer (9/03-9/05,  3/09-7/09, 2/15-5/17), acting Professor in Pharmacology (8/07-2/09) and Academy Research Fellow (1/07-7/07, 8/09-1/15). Savontaus started as an Assistant Professor (tenure track) of Pharmacology and Therapeutics in 6/2017. She has a part-time affiliation as a physician in Clinical Pharmacology in University Hospital of Turku.


Eriika Savontaus is the responsible teacher in the courses of Pharmacology and Clinical Pharmacology. She is involved in organizing doctoral training as the director of Drug Research Doctoral Program. She has supervised PhD thesis of five doctoral candidates and Master's thesis of 11 students.


Obesity with related metabolic and cardiovascular diseases is an increasing problem, but current means to prevent and treat obesity are clearly insufficient. Research of Savontaus group aims to identifying novel means of intervention. The main interest is in two neuropeptides, NPY (neuropeptide Y) and POMC (melanocortins), that play key roles in the regulation of body weight.  They are working to understand the tissue-specific mechanisms of NPY and melanocortin action in order to facilitate drug development for metabolic and cardiovascular diseases. Furthermore, the aim is  to understand the impact of the genetics and epigenetics of these genes on the risk of cardiometabolic diseases and whether the epigenetic inheritance of metabolic diseases could be prevented.


Sort by:

Denosumabi (2019)

(D2 Artikkeli ammatillisessa kokoomateoksessa)

Raloksifeeni (2019)

(D2 Artikkeli ammatillisessa kokoomateoksessa)

Metformiini (2019)

(D2 Artikkeli ammatillisessa kokoomateoksessa)